^
Association details:
| Biomarker: | HER-2 mutation |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Nerlynx (neratinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Tolerability of neratinib in older adults with HER2 positive or HER2 mutated metastatic breast cancer.
Published date:
05/28/2020
Excerpt:
Median number of cycles completed was 3 (0-13): 1/25 (4%) pts had a partial response, 11/25 (44%) had stable disease, 12/25 (48%) had progression of disease, and 1/25 (4%) was not evaluable for response. PFS was 2.6 months (95% CI [2.56-5.26]). The median OS was 17.4 months (95% CI [10.3, NA])....Neratinib is safe in older adults with HER2 positive or HER2 mutated MBC.
DOI:
10.1200/JCO.2020.38.15_suppl.e13018
Trial ID:
